It has been known for many years that cytolytic T lymphocytes that spe
cifically recognize the tumor cells of the same patient can be derived
from the blood of melanoma patients. Several of the antigens recogniz
ed by these antitumor T lymphocytes have now been completely identifie
d. Some of them are sufficiently tumor-specific to envision their use
as antitumor vaccines in selected cancer patients.